“`html
Alnylam Pharmaceuticals: Is the Biotech Stock Currently Undervalued?
Table of Contents
Investors questioning weather alnylam Pharmaceuticals’ (NasdaqGS:ALNY) current share price reflects its true value will find a detailed analysis of the numbers here. The stock closed at US$359.27 on Thursday, demonstrating a strong one-year return of 45.9% and a five-year return of 108.4%. Though, recent performance shows a 9.8% decline over the past week, a 9.3% drop in the last 30 days, and a year-to-date decrease of 10.2%.
Recent developments surrounding Alnylam have centered on its RNA interference-based drug pipeline, key regulatory achievements, and ongoing clinical trial results. These factors substantially influence investor perceptions of future cash flows and associated risks, providing crucial context for recent price movements and shaping valuation expectations. According to valuation checks, Alnylam currently scores 4 out of 6, prompting questions about how different valuation methods assess a company of this nature and whether a more comprehensive approach could offer a more nuanced viewpoint.
Discounted Cash Flow Analysis Points to Undervaluation
A Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting future cash flows and discounting them back to the present, accounting for a required rate of return. For Alnylam pharmaceuticals, a 2 Stage Free Cash Flow to Equity approach is utilized. The latest twelve-month free cash flow stands at approximately $195.7 million. Analysts project free cash flow to reach $4.45 billion by 2030, wiht intermediate years between 2026 and 2035 ranging from $1.62 billion to $6.41 billion before discounting.
Based on these projections, the DCF model estimates an intrinsic value of around $860.33 per share. Compared to the recent share price of $359.27, this suggests the stock is currently trading significantly below its intrinsic value.
Price-to-Sales Ratio Analysis
The Price-to-Sales (P/S) ratio is a valuation metric that compares a company’s stock price to its revenue. It’s tailored to the company, it can be more informative than broad industry comparisons.
With a current P/S of 14.79x versus a Fair Ratio of 16.29x, the stock appears slightly undervalued on this measure.
Result: UNDERVALUED
The NasdaqGS:ALNY P/S Ratio is as of January 2026. Investors interested in exploring other opportunities can discover 1445 companies where insiders are demonstrating confidence through significant growth investments.
refining Your Alnylam pharmaceuticals Valuation Narrative
Earlier, we highlighted a more sophisticated approach to valuation. on Simply Wall St’s Community page, investors can create “Narratives” – customized scenarios for Alnylam Pharmaceuticals. These narratives link specific forecasts for revenue, earnings, and margins to arrive at a fair value, which is then compared to the current price. The system dynamically updates the Narrative as new data and earnings reports are released.
for example, one investor might build an optimistic Alnylam case with price targets in the US$583 range, while another might focus on a more conservative view around US$236. Narratives clearly illustrate how different assumptions translate into vastly different valuations and potential buy or sell decisions.
Do you believe there’s more to the story for Alnylam Pharmaceuticals? Head over to our Community to see what others are saying!
[NasdaqGS:ALNY 1-Year Stock Price Chart] .
this article by Simply Wall St is for general informational purposes only. We provide commentary based on historical data and analyst forecasts using an unbiased methodology, and our articles are not intended as financial advice. It does not constitute a recommendation to buy or sell any stock and does not consider your individual objectives or financial situation. We aim to provide long-term focused analysis driven by basic data. Our analysis may not reflect the latest price-sensitive company announcements or qualitative information.Simply wall St has no position in any stocks mentioned.
New: Manage All your Stock Portfolios in One Place. Connect an unlimited number of portfolios, receive alerts for Warning Signs or risks, and track the Fair Value of your stocks. Try a Demo Portfolio for Free.
Have feedback on this article? Concerned about the content? Get in touch with us directly or email editorial-
